Even after beating its competitors to market with its weight loss drug Qsymia, Vivus (NASDAQ:VVUS) sales have left investors wanting. At roughly $160 per month, the price was causing a 30% abandonment rate with patients. But now, a revised Aetna (NYSE:AET) clinical policy bulletin deemed weight loss drugs Qsymia and Arena Pharmaceutical's (NASDAQ:ARNA) Belviq as medically necessary, potentially expanding coverage, and consequently boosting both initial sales and continued use of the drug for many patients. The announcement has caused share prices of several drug makers in this space to jump.
Editors Note: In this video, it is implied that drugs by GlaxoSmithKline and Pfizer were also added to Aetna's clinical policy bulletin, when they were already listed.
Brenton Flynn has no positions in the stocks mentioned above. David Williamson has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline. Motley Fool newsletter services recommend GlaxoSmithKline and McKesson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
3 Top Dividend Stocks With Yields Over 4%
High-yield stocks have gotten harder to find in the current bull market, but these three should please even the pickiest income investors.
3 High-Yield Stocks Still Worth Buying
All three companies pay at least double the average yield of the S&P 500.
Is a Dividend Cut Coming From GlaxoSmithKline plc?
Is the company's rich yield an opportunity for investors, or a warning of trouble ahead?